Semler Scientific (NASDAQ:SMLR) Coverage Initiated at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald initiated coverage on shares of Semler Scientific (NASDAQ:SMLR) in a research note issued to investors on Monday, MarketBeat.com reports. The firm set an “overweight” rating and a $61.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 66.67% from the stock’s current price.

Several other brokerages also recently commented on SMLR. Maxim Group upgraded shares of Semler Scientific to a “strong-buy” rating and set a $95.00 target price for the company in a report on Wednesday, July 9th. Benchmark began coverage on Semler Scientific in a report on Tuesday, July 8th. They set a “buy” rating and a $101.00 price target for the company. Finally, Wall Street Zen lowered shares of Semler Scientific from a “buy” rating to a “sell” rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Semler Scientific Price Performance

Semler Scientific stock opened at $36.60 on Monday. The company has a market cap of $504.71 million, a price-to-earnings ratio of -14.02 and a beta of 1.39. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.51 and a current ratio of 0.52. Semler Scientific has a 1 year low of $21.77 and a 1 year high of $81.56. The firm has a 50 day moving average price of $38.58 and a 200 day moving average price of $40.54.

Semler Scientific (NASDAQ:SMLR) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter. The firm had revenue of $8.84 million for the quarter. Semler Scientific had a negative net margin of 60.69% and a positive return on equity of 19.75%.

Institutional Investors Weigh In On Semler Scientific

A number of institutional investors have recently added to or reduced their stakes in the company. SummerHaven Investment Management LLC lifted its holdings in shares of Semler Scientific by 2.0% during the 2nd quarter. SummerHaven Investment Management LLC now owns 23,570 shares of the company’s stock valued at $913,000 after buying an additional 464 shares during the last quarter. Kovitz Investment Group Partners LLC grew its stake in Semler Scientific by 2.2% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 22,885 shares of the company’s stock valued at $1,236,000 after acquiring an additional 501 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Semler Scientific by 318.3% in the 4th quarter. NewEdge Advisors LLC now owns 732 shares of the company’s stock valued at $40,000 after purchasing an additional 557 shares during the period. BNP Paribas Financial Markets bought a new position in Semler Scientific during the fourth quarter worth about $30,000. Finally, Cambridge Investment Research Advisors Inc. grew its position in Semler Scientific by 10.2% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 6,226 shares of the company’s stock valued at $225,000 after acquiring an additional 576 shares during the last quarter. Hedge funds and other institutional investors own 49.37% of the company’s stock.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.